Exonic splicing enhancers, sgRNAs, gene editing tools and uses associated with Duchenne muscular dystrophy

Exon splicing enhancers and sgRNAs, combined with AAV vectors and AID-Cas9 fusion proteins, address the limitations of current DMD treatments by modifying pathogenic mutations, restoring dystrophin protein expression, and improving muscle and heart function in DMD models.

JP7591847B2Active Publication Date: 2024-11-29WESTLAKE UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023515078
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-09-02
Filing Date
2020-09-30
Publication Date
2024-11-29
Estimated Expiration
2040-09-30

AI Technical Summary

Technical Problem

Current treatments for Duchenne muscular dystrophy (DMD) are limited and often only alleviate symptoms, with no cure available for patients with mutations outside exon 53, and existing gene editing tools face challenges in therapeutic efficacy, cost, and continuous administration.

Method used

Development of exon splicing enhancers and sgRNAs, combined with a gene editing tool using AAV vectors and AID-Cas9 fusion proteins, to target and modify pathogenic mutations in the DMD gene, specifically inducing exon skipping and restoring dystrophin protein expression.

Benefits of technology

The gene editing tool effectively modifies pathogenic mutations in DMD mouse models and human cells, restoring dystrophin protein function, improving muscle and heart function, and extending lifespan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591847000001
    Figure 0007591847000001
  • Figure 0007591847000002
    Figure 0007591847000002
  • Figure 0007591847000003
    Figure 0007591847000003
Patent Text Reader

Abstract

Exon splicing enhancers, sgRNAs, gene editing tools, and uses associated with Duchenne muscular dystrophy. The related exon splicing enhancers, sgRNAs, and gene editing tools are useful for the production of drugs to treat Duchenne muscular dystrophy. A gene editing tool designed based on a mutant cytosine deaminase AID and a mutant Cas9 gene can be used with an adeno-associated virus (AAV) as a vector to perform site-specific modifications to mammalian genomes. By optimizing the coding nucleic acid sequence and element structure of the editing tool, site-specific modifications of mammalian genetic material DNA can be efficiently achieved. By targeting and manipulating the nucleic acid sequence containing the disease-causing mutation, the pathogenic mutation is prevented from remaining in the amino acid sequence of the mature protein or from functioning. This achieves the goals of treating various rare genetic diseases caused by gene mutations, while also achieving high efficiency, safety, and stability.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the field of gene therapy, and relates to the modification treatment of dystrophic exon splicing enhancers, sgRNAs, and gene editing tools associated with Duchenne muscular dystrophy for pathogenic mutations of gene mutation-type genetic diseases in mammals (experimental animal models and human patients), particularly in mouse models and human patients with Duchenne muscular DMD for gene editing therapy. [Background technology]

[0002] According to the definition of the World Health Organization (WHO), a rare disease is a disease that is not commonly seen in a certain region, with the number of patients accounting for 0.065% to 0.1% of the total population. Many of these diseases have a difficult to find mechanism of onset, and there are few specific treatments, which cause great harm to the physical health of patients and place a huge burden on their families and society. Due to China's very large population base, the absolute number of rare disease cases cannot be ignored, and in recent years, scientific researchers and clinical experts have attached great importance to rare diseases and have attracted their attention. In May 2018, five departments of China's National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, National Medical Products Administration, and National Administration of Traditional Chinese Medicine jointly published the "First Rare Disease Catalog," which listed 121 types of diseases, indicating that rare diseases have gained more importance and attention in China.

[0003] The pathogenesis of rare diseases is often due to gene mutations, leading to many complex clinical findings. Due to the limited diagnostic methods, patients are generally grouped together as having a single disease after the onset of clinical symptoms early in the disease course, and only after long-term treatment is there any improvement can they be further judged to have a rare undiagnosed disease. Therefore, there is a need for progress in the related research of rare undiagnosed diseases / rare diseases, including but not limited to exploring the pathogenesis, optimizing diagnostic methods, tracking the pathogenesis, screening drug targets, and developing specific gene drugs in combination with gene editing technology. At the same time, the discovery and improvement of special rare disease animal models can also promote a comprehensive understanding of rare diseases and the development of specific drugs. The present invention focuses on muscular dystrophy, a rare disease that was discovered early in clinical practice but for which effective treatment has been lacking for a long time. It focuses on Duchenne muscular dystrophy (DMD), combines it with a newly discovered mouse model, develops and optimizes a gene therapy for the disease, and applies the gene therapy to the human genome sequence.

[0004] Duchenne muscular dystrophy (DMD) is an X-chromosome genetic disease, with approximately one affected patient per 4,000 male newborns. Its etiology is the lack of expression due to a gene mutation in dystrophin. Myocardial tissue damage and dysfunction are the most fatal threats to DMD patients. For a long time, DMD has not had a sufficiently effective treatment, and the treatments given in clinical practice are limited to symptom relief, for example, angiotensin inhibitors are used to relieve the disorders caused by myocardial degeneration, such as perindopril and several types of β-receptor blockers. At the same time, with the improvement of medical means, interventional therapies including cardiocirculatory support systems and respiratory support systems have also become more helpful in alleviating the symptoms of DMD patients. However, these treatments essentially cannot improve the quality of life of DMD patients, but only extend the lifespan of DMD patients, so the progressive degeneration of cardiac function is still the leading cause of death in DMD patients.

[0005] With the development of molecular biology, combined with clinical data analysis, patients who have the same mutation in the gene coding for dystrophin protein but do not show the same severe pathological process as DMD patients have been found. Such patients are called Becker muscular dystrophy (BMD) patients, and their dystrophin gene mutation does not lead to the complete destruction of the protein open reading frame, so that dystrophin protein with some biological function can be produced, and severe myocardial dysfunction and other muscle function defects do not appear. In contrast to the severe pathological process of DMD patients, the lifespan of BMD patients is not significantly affected, and they can return to daily life almost like healthy people. The emergence of such BMD patients has given scientific researchers an inspiration: it may be possible to induce exon skipping of the mutations in DMD patients without affecting the protein reading frame, so that a dystrophin protein close to the full length can be produced and used to treat DMD patients. Such an idea has been put into practice in recent years, and currently, several types of mutation exons can already be treated with such a plan, and some of them have been approved for clinical trials.

[0006] By the end of 2019, only a limited number of specific drugs for DMD have been approved for sale worldwide. Among them, Sarepta Therapeutics is a biotechnology company dedicated to developing rare disease treatments through precision gene therapy. Gologirsen, researched and developed by the company, was approved by the US FDA through fast track process and marketed on December 12, 2019, for the treatment of DMD patients diagnosed with exon 53 gene mutations through exon skipping. It is estimated that about 8% of DMD patients have this mutation. The essence of gologirsen is an antisense oligonucleotide that acts by targeting the sequence of the dystrophin protein. Therefore, there is still a large gap in drugs designed for other mutation sites. Currently, there is fierce competition around the world, including drugs for DMD that have already entered clinical trials, but the demand is still huge. Statistics show that five drugs for DMD are currently on the market, six are in phase III clinical trials, 19 are in phase II clinical trials, and five have just entered phase I clinical trials.

[0007] It should be noted that among human DMD patients, these drugs are only suitable for one type of patient with a certain mutation, and other DMD patients still lack sufficient specific therapeutic drugs. Eteplirsen, researched and developed by Sarepta Therapeutics, is an antisense phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic drug and is the company's first commercially available (2016) drug to treat DMD. However, these already marketed drugs often have disadvantages such as low therapeutic efficiency, need for continuous administration, and high cost. Gene editing therapeutic methods can directly target and modify the pathogenic mutations of gene mutation-type genetic diseases, and once edited, it can basically cure the disease, which has great advantages. Currently, there are still few applications of gene editing tools to treat rare genetic diseases around the world, not just DMD. Summary of the Invention [Problem to be solved by the invention]

[0008] The objective of the present invention is to provide an exon splicing enhancer, sgRNA, and gene editing tool associated with Duchenne muscular dystrophy as a drug for gene editing therapy in mammals (disease animal models and human patients) for rare genetic mutation-type diseases. [Means for solving the problem]

[0009] In a first aspect, the present invention provides an exon splicing enhancer associated with Duchenne muscular dystrophy, the exon splicing enhancer targeting exon 51 of the human DMD gene, the exon splicing enhancer comprising the nucleotide sequence: 1) the sequence shown in SEQ ID NO: 21 and its reverse complement; 2) the sequence shown in SEQ ID NO: 22 and its reverse complement; 3) the sequence shown in SEQ ID NO: 23 and its reverse complement; 4) The sequence shown in SEQ ID NO: 24 and its reverse complement.

[0010] By modifying or blocking elements such as the exon splicing enhancer (ESE), exon skipping of exon 51 of the DMD gene can be induced, enabling gene editing therapy in mammals. For example, CRISPR nucleases disrupt the structure of ESEs with insertions and deletions (Indels) introduced by double-stranded DNA breaks, and antisense oligonucleotides (ASOs) target the corresponding element sites in pre-mRNA in cells and prevent them from remaining in the amino acid sequence of the final protein.

[0011] In a second aspect, the present invention also provides a single-strand guide RNA (sgRNA) capable of targeting a specific genome associated with Duchenne muscular dystrophy, the sgRNA comprising the sequence: an sgRNA against the Dmd-E4 mouse mutation site, the nucleotide sequence of which is shown in SEQ ID NO:4; an sgRNA against exon 50 of the human DMD gene, the nucleotide sequence of which is shown in SEQ ID NO:7; sgRNA-1, the nucleotide sequence of which is shown in SEQ ID NO:8, against exon 51 of the human DMD gene; sgRNA-2, the nucleotide sequence of which is shown in SEQ ID NO:9, against exon 51 of the human DMD gene; sgRNA-3, the nucleotide sequence of which is shown in SEQ ID NO:10, against exon 51 of the human DMD gene; sgRNA-4, whose nucleotide sequence is shown in SEQ ID NO:11, against exon 51 of the human DMD gene; sgRNA-5, the nucleotide sequence of which is shown in SEQ ID NO:12, against exon 51 of the human DMD gene; sgRNA-6, whose nucleotide sequence is shown in SEQ ID NO:13, against exon 51 of the human DMD gene; sgRNA-7, whose nucleotide sequence is shown in SEQ ID NO:14, against exon 51 of the human DMD gene; sgRNA-8, whose nucleotide sequence is shown in SEQ ID NO:15, against exon 51 of the human DMD gene; sgRNA-9, the nucleotide sequence of which is shown in SEQ ID NO: 16, against exon 51 of the human DMD gene; sgRNA-10, the nucleotide sequence of which is shown in SEQ ID NO:17, against exon 51 of the human DMD gene; sgRNA-11, the nucleotide sequence of which is shown in SEQ ID NO:18, against exon 51 of the human DMD gene; sgRNA-12, the nucleotide sequence of which is shown in SEQ ID NO:19, against exon 51 of the human DMD gene; sgRNA-13, the nucleotide sequence of which is shown in SEQ ID NO:20, against exon 51 of the human DMD gene.

[0012] The sgRNAs can be combined with gene editing tools and used to manufacture drugs to treat Duchenne muscular dystrophy.

[0013] In a third aspect, the present invention provides a gene editing tool related to Duchenne muscular dystrophy, comprising a fusion protein of cytosine deaminase and a Cas mutant, an sgRNA according to claim 2, and a vector. The vector is a commonly used biological plasmid, such as an AAV vector plasmid, pCDNA3.1 plasmid, etc. Furthermore, the cytosine deaminase may be AID, apobec, etc., but preferably, the cytosine deaminase is AID, and the amino acid sequence and nucleic acid sequence of the fusion protein of AID and the Cas9 mutant are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

[0014] Moreover, said gene editing tool is packaged by adeno-associated virus vector AAV.Adeno-associated virus AAV can deliver AID-Cas9 fusion protein and the nucleic acid sequence expressing sgRNA to target cell, and express protein with DNA editing function and sgRNA molecule with guide function in cell, in which sgRNA can guide AID-Cas9 fusion protein to specific genomic site in target cell, induce modification and inactivate pathogenic mutation to realize the purpose of treating disease. Furthermore, the promoter of the adeno-associated virus vector AAV is a Syn100 promoter or a promoter designed based on ck8a, mhck7, etc. Furthermore, the nucleotide sequence of the adeno-associated virus vector AAV is shown in SEQ ID NO:3.

[0015] The present invention also provides the use of the above gene editing tool in the manufacture of a medicament for treating Duchenne muscular dystrophy. The beneficial effects of the present invention are as follows: The present invention takes the pathogenic mutations of DMD mouse models and human DMD patients as examples, and by designing and constructing gene editing tools, it has realized the treatment of DMD mouse models at the in vivo level using adeno-associated virus AAV. At the same time, a gene editing method has been designed for the pathogenic mutations of human DMD patients, and the modification of the pathogenic mutations at the cellular level has been realized. The present invention provides a creative treatment method for gene mutation-type genetic rare diseases, and is expected to have a groundbreaking therapeutic effect on many genetic rare diseases. Description of the drawings [Brief description of the drawings]

[0016] [Figure 1] Figure 1 shows the composition of functional elements including gene editing tools, in which A is separate viral packaging and B is joint viral packaging. [Diagram 2] Figure 2 shows a flow diagram of treatment for the novel DMD mouse disease model Dmd-E4, in which A is preventive treatment in newborn mice and B is restorative treatment in adult mice. [Diagram 3] Figure 3 shows the results of sequencing some of the AAV plasmids: (A) comparative sequencing results of the Syn100 promoter, (B) comparative sequencing results of the AID and Cas9 mutant fusion proteins, and (C) comparative sequencing results of the U6 promoter.

[0017] [Figure 4]Figure 4 is a schematic diagram of the successful repair of the disease phenotype due to defective dystrophin expression in Dmd-E4 mice by AAV treatment. In the figure, A shows reverse transcription PCR performed on RNA in the hearts of treated Dmd-E4 mice, primers were designed from exon 3 and exon 5, and exon 4 with a mutation was detected as skipped, Dmd is the gene encoding mouse dystrophin protein, and Gapdh is the internal reference for PCR. In figure B, the ratio of the amount of nucleic acid contained in the skipped band of exon 4 and the non-skipped (i.e., containing) band was confirmed using a quantitative method by capillary electrophoresis. In figure C, Sanger sequencing was performed on the exon-skipped band to confirm that exon 4 was completely skipped and exon 3 and exon 5 were linked. In figure D, immunoblot detection was performed on the protein in the hearts of treated Dmd-E4 mice, samples from WT mice and untreated mice were used as positive and negative controls, and VCL is the internal reference for large molecular weight. In figure E, quantitative statistics of the bands in figure D. Figure F shows the expression of dystrophin protein in the hearts of treated Dmd-E4 mice using immunofluorescence staining, including two post-treatment samples. Figure G shows the small animal cardiac ultrasound detection to determine whether the alterations in cardiac-related physiological structures of Dmd-E4 mice were repaired after AAV treatment. Figure H shows the quantification of Figure F, quantifying the proportion of dystrophin-positive cells. P values: *p<0.05, **p<0.01, ***p<0.001.

[0018] [Diagram 5]Figure 5 shows the successful recovery of muscle function and prolongation of survival in Dmd-E4 mice with AAV treatment. Figure A shows the content of creatine kinase in the serum of treated Dmd-E4 mice, and samples from WT and untreated Dmd-E4 mice were used as controls. Figure B shows the degree of myocardial inflammatory cell infiltration and fibrosis in treated Dmd-E4 mice evaluated by HE staining and Masson staining. Figure C shows the quantitative statistics of the recovery of myocardial fibrosis in treated Dmd-E4 mice based on the results of Masson staining. Figure D shows the degree of spinal curvature in Dmd-E4 mice detected by micro-CT, and samples from WT and untreated mice were used as controls. Figure E shows the quantitative statistics of the degree of spinal curvature in Figure D. Figure F shows the width of the drop in the cyclic contraction process of the maximum tension of the whole-body muscles of treated Dmd-E4 mice detected by the tension device. G: Survival statistics of WT mice and AAV-treated and untreated Dmd-E4 mice. H: Molecular biological evidence of gene editing in cardiomyocytes of Dmd-E4 mice. Reverse transcription PCR on pre-mRNA of corresponding cells followed by high-throughput sequencing revealed the predicted mutations near the site targeted by sgRNA, providing a molecular basis and rationale for therapeutic treatment of the cardiac disease phenotype in Dmd-E4 mice. *p<0.05, **p<0.01, ***p<0.001.

[0019] [Figure 6]Figure 6 shows that gene editing tools successfully induced the corresponding modification of the DMD gene in human cells. Figure A shows that two sgRNAs were successfully screened in K562 cell line to induce exon 51 skipping, and the figure shows the results of reverse transcription PCR performed on RNA extracted from edited K562 cells, which showed that the combination of two sgRNAs can efficiently induce K562 cells with exon 50 deletion to skip exon 51. Figure B shows that exon 51 skipping of the DMD gene was induced in normal human iPS cells and cells with DMD exon 50 deletion. Figure C shows that the expression of dystrophin protein was restored in edited iPS cells by immunofluorescence detection. Figure D shows that the expression of dystrophin protein was restored in edited iPS cells by Western blotting. Figure E shows the quantitative statistics of the recovery of protein expression in Figure D. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Specific embodiments The present invention uses the pathogenic mutations of DMD mouse models and human DMD patients as examples, and realizes modification of the pathogenic mutations by designing and constructing gene editing tools. The present invention will be further described below with reference to specific examples and drawings.

[0021] Example 1 AAV viruses carrying gene editing tools The gene editing tool designed by the present invention takes AID as an example, as shown in FIG. 1, and clones the corresponding sequence into an AAV plasmid, and includes the following steps:

[0022] First, a pAAV2 backbone vector (purchased from addgene, but not limited to this) was double enzymatically cut based on the XhoI and NotI enzyme cleavage sites. At the same time, the amino acid sequence of the fusion protein of AID and Cas9 in the gene editing tool was designed, and the amino acid sequence and nucleic acid sequence are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. After optimizing the codons, the double-stranded DNA fragment was directly synthesized and linked to the AAV backbone vector together with elements such as the Syn100 promoter and tail addition signal to obtain an AAV vector plasmid expressing the AID-Cas9 mutant fusion protein, the sequence of which is shown in SEQ ID NO: 3. In addition, the method of primer synthesis and PCR may be used to link the sequences of the U6 promoter, H1 promoter, and 7SK promoter with sgRNA that recognizes the cleavage site of the exon of the pathogenic mutation, and at the same time, green fluorescent protein and related elements are expressed by the Syn100 promoter and tail addition signal, thereby increasing the protein expression tag and promoting the improvement of gene editing efficiency. Alternatively, a gene editing tool can be constructed using a combined virus packaging AAV plasmid, which contains the expression element for the AID and Cas9 fusion protein, as well as the U6 promoter and sgRNA targeting the exon cleavage site of the pathogenic mutation, to construct an AAV plasmid vector with a 4.9 kbp insertion sequence. Some of the results of cloning the relevant plasmids are shown in Figure 3 below.

[0023] After the construction of the AAV vector plasmid was completed, it was packaged and purified according to the existing literature [Grieger, J., Choi, V. & Samulski, R. Production and characterization of adeno-associated viral vectors. Nat Protoc 1, 1412-1428 (2006).], and the titer was 1 × 10 13 The AAV virus with serotype AAV9 was obtained in 1000 μg / mL. In the case of separate virus packaging, they were mixed in a ratio and used, and in the case of joint virus packaging, they could be used directly for in vivo treatment.

[0024] Example 2 In vivo treatment of DMD model mice with AAV carrying gene editing tools In this embodiment, a novel DMD mouse disease model Dmd-E4 with cardiac dysfunction is selected, which can be purchased from Jiangsu Jisu Yaokang Biotechnology Co., Ltd., but is not limited thereto. Dmd-E4 shows phenotypes such as myocardial hypertrophy and fibrosis in the heart in 6-8 weeks, and severe cardiac function degeneration in about 8 months. This process favorably simulates the pathological process of the heart in DMD patients. For this model, a gene editing tool is designed with cytosine deaminase and Cas9 to target the exon of the pathogenic mutation, induce mutation near its 5' cleavage site, skip, and leave the expression of dystrophin protein to the maximum extent without affecting the open reading frame of the protein, and restore its biological function.

[0025] Specifically, a gene editing tool was constructed according to the method of Example 1, in which the sequence of the designed sgRNA for the mutation site of Dmd-E4 mouse is shown in SEQ ID NO: 4, and the sequence of the obtained AAV vector plasmid expressing the sgRNA for the mutation site of Dmd-E4 mouse is shown in SEQ ID NO: 5. The corresponding sequence of the AID-Cas9 fusion protein and the sgRNA for Dmd-E4 mouse in the same AAV vector plasmid is shown in SEQ ID NO: 6. The virus with serotype AAV9 was selected, synthesized and purified, and used to treat Dmd-E4 mice in two ways: preventive treatment in neonatal mice and corrective treatment in adult mice, as shown in Figure 2.

[0026] (A) Gene therapy in newborn mice Group assignment: Homozygous KO female and male Dmd-E4 mice were mated. After the female mice became pregnant, the female and male mice were placed in separate cages and observed every two days to see if the pregnant female mice gave birth. When newborn Dmd-E4 mice were born, their gender was observed and 3-5 male mice were selected as the experimental group, and another 3-5 male mice were selected as the negative control group. Administration: 50-75 μL of adeno-associated virus (AAV) carrying the gene editing tool (titer 1013 Control mice were given 100 mg of 10 ...

[0027] Sample collection and detection: When the mice were about 2 months old, 3-5 WT male mice of the same age were taken in addition to the experimental and control groups, and were treated as follows: After anesthetizing the mice, we first performed functional tests of the tibialis anterior muscle, cardiac ultrasound examination, etc., and then collected cardiac arterial and venous blood, sacrificed the mice, separated the serum by centrifugation, and stored it at -80℃. At the same time, we collected tissues such as cardiac muscle, skeletal muscle, tibialis anterior muscle, dorsal muscle, liver, brain, and kidney, and extracted their proteins, RNA, and genomic DNA, and left enough tissues for immunofluorescence staining, hematoxylin-eosin staining, etc.

[0028] As shown in Figure 4A, reverse transcription PCR was performed on RNA in the hearts of treated Dmd-E4 mice, primers were designed from exon 3 and exon 5, and exon 4 with the mutation was detected as skipped. At the same time, a quantitative method using capillary electrophoresis was used to confirm the ratio of the amount of nucleic acid contained in the exon 4 skipped band and the non-skipped (i.e., included) band. The results are shown in Figure 4B. Furthermore, Sanger sequencing was performed on the exon 4 skipped band, and as shown in Figure 4C, exon 4 was completely skipped and exon 3 and exon 5 were linked. Figure 3D-F shows immunoblot detection of proteins in the hearts of mice, in which Figure 4D is the band diagram, Figure 3E is the quantitative statistics of the band in the 3D diagram, and Figure 4F is the expression status of dystrophin protein. The results show that the expression of dystrophin protein was significantly restored in treated Dmd-E4. In addition, we used small animal cardiac ultrasound detection to examine whether the alterations in cardiac-related physiological structures of Dmd-E4 mice were restored after AAV treatment. The results, shown in Figure 4G, indicate that the cardiac-related physiological structures of treated Dmd-E4 mice were essentially restored.

[0029] In addition, we verified whether the muscle function and survival time of Dmd-E4 mice were restored and extended. Figure 5A shows the measurement results of serum creatine kinase content in mice, which shows that compared with the samples of WT and untreated Dmd-E4 mice, the treated Dmd-E4 mice had a significantly reduced creatine kinase content. HE staining and Masson staining were used to evaluate the infiltration of myocardial inflammatory cells and the degree of fibrosis in the treated Dmd-E4 mice. At the same time, the results of Masson staining were used to quantitatively statistic the recovery of the degree of myocardial fibrosis in the treated Dmd-E4 mice. The results are shown in Figures 5B-5C, which show that the degree of myocardial fibrosis in the treated Dmd-E4 mice was significantly improved.

[0030] In addition, the degree of spinal curvature of Dmd-E4 mice was detected by micro-CT (Figure 5D-5E), and the amplitude of the drop in the maximum tension of the whole-body muscles of Dmd-E4 mice treated with a tension device during the cyclic contraction process was detected (Figure 5F). Both results showed that after treatment of Dmd-E4 mice, the degree of spinal curvature was alleviated, and at the same time, the tension of the whole-body muscles of the mice was increased, and the survival time of Dmd-E4 mice was significantly extended. Figure 5H shows the molecular biological evidence of gene editing in cardiomyocytes of Dmd-E4 mice. Reverse transcription PCR was performed on the pre-mRNA of the corresponding cells, followed by high-throughput sequencing, and it was found that there was a predicted mutation near the site targeted by sgRNA, which provides a molecular basis and rationale for treating the cardiac disease phenotype of Dmd-E4 mice. The above results demonstrate that the gene editing tool of the present invention can effectively treat and prevent newborn Dmd-E4 mice.

[0031] (B) Gene therapy in adult mice Grouping: 4-6 week old homozygous KO Dmd-E4 mice were used as the experimental group and were given gene therapy, while 4-6 week old homozygous KO Dmd-E4 mice were used as the control group and were treated with an equal volume of PBS. Administration: Approximately 50 μL of adeno-associated virus AAV (titer 10) carrying the gene editing tool13 The mice were administered 100 mg of 10 ...

[0032] Sample collection and detection: About two months after the mice were treated, 3-5 WT male mice of the same age were taken from the experimental and control groups, and were treated as follows: After anesthetizing the mice, we first performed functional tests of the tibialis anterior muscle and cardiac ultrasound examination, and then collected cardiac arterial and venous blood, sacrificed the mice, centrifuged to separate the serum, and stored it at -80℃. At the same time, we collected tissues such as myocardium, skeletal muscle, tibialis anterior muscle, dorsal muscle, liver, brain, and kidney, and extracted their proteins, RNA, and genomic DNA, and left enough tissues for immunofluorescence staining, hematoxylin-eosin staining, etc.

[0033] The results demonstrated that AAV could be used as a delivery vehicle for gene editing tools to achieve efficient gene repair of the mutated exon. In the treated Dmd-E4 mice, skipping of the pathogenic exon was observed in both the myocardium and multiple muscle tissues, which restored the expression of dystrophin protein and obviously repaired the myocardial injury phenotype, and enabled the treatment of adult Dmd-E4 mice.

[0034] Example 3 Successful restoration of dystrophin protein expression by gene editing in a DMD model of human induced pluripotent stem cells (iPSCs) In the present invention, gene editing therapy for human cells was also successfully carried out. First, induced pluripotent stem cells (iPSCs) were constructed from peripheral blood mononuclear cells of healthy individuals, and then exon 50 of the dystrophin coding gene DMD was specifically deleted by the CRISPR-cas9 method, and a shift mutation was made in the coding sequence of the dystrophin protein, thereby constructing a mutant type simulating a DMD patient, which became a suitable DMD disease model cell. For this cell, an AID and Cas9 fusion protein and a corresponding sgRNA sequence were designed to target a series of potential exon splicing regulatory elements in exon 51 of the DMD gene, and the sgRNAs used in this example were sgRNA-12 shown in SEQ ID NO: 19 and sgRNA-13 shown in SEQ ID NO: 20, and sgRNA-12 mainly targets the exon splicing enhancers shown in SEQ ID NO: 21 and SEQ ID NO: 22. sgRNA-13 mainly targets the exon splicing enhancer shown in SEQ ID NO: 24.

[0035] The above two sgRNA-12 were obtained by screening in human K562 cell line, and can induce exon 51 skipping. As shown in FIG. 6A, RNA was extracted from edited K562 cells, and reverse transcription PCR was performed. The results showed that both sgRNAs can induce mutations, and when used together, it is possible to efficiently induce K562 cells with exon 50 deletion to skip exon 50. At the same time, the skipping of exon 51 can be induced to restore the open reading frame of dystrophin protein in iPS cells with exon 50 deletion, and further reconstruct the expression of dystrophin protein. Specific embodiments are as follows:

[0036] 3.1 Induction of differentiation of iPS cells into cardiomyocytes (1) Human iPS cells cultured in Matrigel were digested with Accutase for 6 min at 37° C., the reaction was stopped with DMEM medium, the cells were collected, centrifuged at 1500 rpm for 3 min, and counted under a microscope. (2) iPS cells were plated onto a 12-well plate coated with Matrigel at a cell density of 10,000-20,000 cells / cm. 2 The medium is adjusted to be 10 μM, and the iPS cells are cultured in mTeSR1 medium. 10 μM of ROCK inhibitor (Y-27632) is added and cultured for 4 days. The medium is replaced with fresh medium every day, and it is not necessary to add the ROCK inhibitor when changing the medium. (3) After culturing the cells for 4 days, the mTeSR1 medium was replaced with RPMI / B27-insulin medium containing 6 μM CHIR99021, and the cells were cultured for 2 days.

[0037] (4) CHIR99021 stimulation was withdrawn, and the medium was replaced with RPMI / B27-insulin medium and cultured for 1 day. (5) The medium was replaced with RPMI / B27-insulin medium containing 5 μM IWR1, and the cells were cultured for 2 days. (6) IWR1 stimulation was withdrawn, and the medium was replaced with RPMI / B27-insulin medium and cultured for 2 days. After the cell culture medium was replaced with RPMI / B27 medium, the cells were cultured in the medium for a long time, with the medium being replaced once every two days, to obtain human pluripotent stem cells that differentiate into cardiomyocytes.

[0038] 3.2 Transduction of gene-editing tools into human pluripotent stem cells for induction of cardiomyocyte differentiation (1) On the day before transduction, digest iPS cells to be differentiated into cardiomyocytes with Accutase and plate 4 × 10 5 Laid with cells. (2) After about 24 hours, when the cell density of iPS cells differentiating into cardiomyocytes reached about 60%, the cell culture medium was replaced with non-resistant medium. (3) 2.5 μg of a plasmid expressing a fusion protein of AID and a Cas9 mutant (e.g., Lenti-V2-AIDx-nSaCas9 (KKH)-Ugi plasmid), 500 ng of a plasmid expressing UGI (e.g., pCDNA3.1-Ugi), and 1.5 μg of sgRNA plasmid were homogeneously mixed in 150 μl of opti-MEM, and then 2.5 μl of PLUS TM The reagents were added and mixed gently until uniform.

[0039] (4) 12 μl of Lipofectamine LTX and 150 μl of opti-MEM medium were mixed uniformly, and the mixture was added to the plasmid from step (3), mixed gently and uniformly, and incubated at room temperature for 15 min. The reaction product was then added to the iPS cells differentiated into cardiomyocytes from (2). (5) After 48 h transduction, the transduced cells were loaded with 2 μg / ml puromycin and screened for 3 days, after which the reagent was removed and the cells were harvested and analyzed 7 days after transduction.

[0040] 3.3 Detection of relevant indicators for edited iPSCs (1) Genomic DNA was extracted from iPSCs before and after editing, and the corresponding exon 51 mutation was detected. (2) RNA was extracted from iPSCs before and after editing, and reverse transcription PCR was performed to detect whether exon 51 was skipped at the RNA level. The results were shown in Figure 6B, which showed that exon 51 skipping of the DMD gene was induced in normal human iPSCs and cells with DMD exon 50 deletion.

[0041] (3) The expression of dystrophin protein at the protein level for iPSCs before and after editing is considered, and the experimental methods include Western blotting, immunofluorescence staining, etc. Figure 6C shows the results of immunofluorescence detection to confirm that the expression of dystrophin protein is restored in edited iPS cells. Figure 6D shows the results of Western blotting to confirm that the expression of dystrophin protein is restored in edited iPS cells. Figure 6E shows the quantitative statistics of the recovery of protein expression in Figure D.

[0042] The above results indicate that a gene editing method capable of inducing the skipping of exon 51 of the human DMD gene in the K562 cell line was constructed, and a series of sequence elements regulating potential exon skipping were identified. At the same time, this gene editing method was further used to successfully therapeutically modify iPSCs, a DMD disease model cell, and restore dystrophin protein expression. Furthermore, the remaining sgRNA-1 to sgRNA-11 shown in sequence numbers 7 to 18 all target the exon splicing enhancers shown in the corresponding sequence numbers 21 to 24 of the present invention, and when a gene editing tool is constructed using them, it is possible to efficiently induce the skipping of exon 51, thereby realizing the treatment of human DMD.

[0043] Of course, the above examples are merely examples given for clarity of explanation, and are not intended to limit the embodiments. Those skilled in the art may make other variations or modifications based on the above description. It is not necessary to illustrate all the embodiments here. Any variations or modifications that can be easily conceived thereby are still within the scope of protection of the present invention.

Claims

1. 1. An sgRNA targeting an exon splicing enhancer associated with Duchenne muscular dystrophy, the exon splicing enhancer element targeting exon 51 of the human DMD gene, wherein the nucleotide sequence of the exon splicing enhancer element is: 1) the sequence shown in SEQ ID NO:21 and its reverse complement; 2) the sequence shown in SEQ ID NO: 22 and its reverse complement; or 3) The sequence shown in SEQ ID NO: 24 and its reverse complement wherein the sgRNA is an sgRNA comprising: sgRNA-12, the nucleotide sequence of which is set forth in SEQ ID NO: 19, directed against exon 51 of the human DMD gene; and The sgRNA, which is directed against exon 51 of the human DMD gene, consists of sgRNA-13, the nucleotide sequence of which is set forth in SEQ ID NO:

20.

2. The sgRNA of claim 1 for use in the treatment of Duchenne muscular dystrophy.

3. A gene editing tool associated with Duchenne muscular dystrophy, comprising a fusion protein of cytosine deaminase and a Cas mutant, an sgRNA and a vector as described in claim 1.

4. The gene editing tool described in claim 3, wherein the cytosine deaminase is AID, and the amino acid sequence of the fusion protein of AID and the Cas9 mutant is shown in SEQ ID NO:

1.

5. The gene editing tool of claim 3 , packaged by an adeno-associated viral vector AAV.

6. The gene editing tool of claim 5, wherein the promoter of the adeno-associated viral vector AAV is a Syn100 promoter or a promoter based on ck8a or mhck7.

7. The gene editing tool of claim 5, wherein the nucleotide sequence of the adeno-associated virus vector AAV is set forth in SEQ ID NO:

3.

8. A gene editing tool according to any one of claims 3 to 7 for use in the treatment of Duchenne muscular dystrophy.

Citation Information

Patent Citations

  • RNA-modulated oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy

    JP2015509922A

  • RNA-guided gene editing and gene regulation

    JP2016521555A

  • Compositions and methods for correcting dystrophin mutations in human cardiomyocytes

    WO2019152609A1